<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979808</url>
  </required_header>
  <id_info>
    <org_study_id>NAV-0001</org_study_id>
    <nct_id>NCT02979808</nct_id>
  </id_info>
  <brief_title>An Open, Qualitative, Prospective, Multicenter Trial of a Novel Transanal Irrigation System in Spinal Cord Injured Patients.</brief_title>
  <official_title>An Open, Qualitative, Prospective, Multicenter Trial of a Novel Transanal Irrigation System in Spinal Cord Injured Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellspect HealthCare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dentsply International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as an open, prospective, non-controlled, qualitative, multicentre
      study of a novel transanal irrigation system performed in a population of 150 subjects
      suffering from spinal cord injury and confirmed neurological bowel dysfunction. The study is
      expected to last for a total of 1 year (treatment period) with a planned 12- month
      recruitment period and three scheduled site visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in multiple countries, all outside of the United States. The
      study is approved by oversight authorities in the United Kingdom, Germany, Spain, Sweden,
      Denmark, Norway, France, and Italy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neurogenic bowel disfunction symptoms.</measure>
    <time_frame>3 months</time_frame>
    <description>1. The primary objective of this study is to evaluate change in neurogenic bowel dysfunction symptoms between baseline and 3 months use of the Navina™ Smart system, as measured by a patient friendly version of the validated instrument NBD Score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of QoL status</measure>
    <time_frame>Baseline, 3-months, 12-months</time_frame>
    <description>To investigate the change of QoL status in the selected patient population (absolute values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NBD symptoms</measure>
    <time_frame>6-months, 9-months, 12-months</time_frame>
    <description>To investigate NBD symptoms after 6, 9 and 12 months use of Navina Smart system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product use compliance.</measure>
    <time_frame>3-months, 6-months, 9-months, and 12-months</time_frame>
    <description>Study product use compliance (is TAI still performed using the study device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction assessed through patient reported outcome (PRO) variables.</measure>
    <time_frame>3-months and 12-months</time_frame>
    <description>To investigate patient perception and satisfaction of bowel management including TAI therapy and use of the Navina Smart system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of urinary tract infection (UTI).</measure>
    <time_frame>3-months and 12-months</time_frame>
    <description>Investigate frequency of UTI using patient reported outcome (PRO) variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis utilizing QoL data.</measure>
    <time_frame>Baseline, 3-months, and 12-months.</time_frame>
    <description>To perform health economic analyses using QoL data (EQ-5D).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis utilizing patient reported outcome (PRO) variables.</measure>
    <time_frame>Baseline, 3-months, and 12-months.</time_frame>
    <description>To perform health economic analyses using PRO variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thematic analysis of interview data.</measure>
    <time_frame>Baseline, 3-months, and 12-months (or at end of treatment period).</time_frame>
    <description>To understand individual experience of initiating and using TAI for neurogenic bowel dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thematic analysis of interview data.</measure>
    <time_frame>Baseline, 3-months, and 12-months (or at end of treatment period).</time_frame>
    <description>To explore individual perceptions of using TAI compared with other conservative treatments for neurogenic bowel dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thematic analysis of interview data.</measure>
    <time_frame>Baseline, 3-months, and 12-months (or at end of treatment period).</time_frame>
    <description>To explore what influences individuals to continue with or stop using TAI for neurogenic bowel dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, serious adverse events, and adverse device effects.</measure>
    <time_frame>3-months, 6-months, 9-months, 12-months</time_frame>
    <description>To evaluate short- and long-term safety of the product and therapy by assessing adverse events, serious adverse events, adverse device effects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neurogenic Bowel</condition>
  <arm_group>
    <arm_group_label>Navina Smart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navina Smart will be used during 12 months for transanal irrigation (TAI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Navina Smart</intervention_name>
    <description>Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.</description>
    <arm_group_label>Navina Smart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent.

          2. Male or female aged 18 years or older.

          3. Patient with previously confirmed chronic spinal cord injury, either:

               1. Traumatic; at any level and any completeness of injury and ASIA grade
                  classification, or

               2. Non-traumatic; due to infection, inflammation (i.e.; transverse myelitis or
                  ischaemic myelitis), compromised blood supply, a post-ischemic state, etc.

          4. At least 3 months post spinal cord injury at time of consent.

          5. NBD score ≥10, confirmed at Baseline .

          6. Only TAI treatment - naïve patient (not having previously used any particular
             transanal irrigation system, e.g. Peristeen®).

          7. Confirmed NBD refractory to conservative therapy and judged eligible for transanal
             irrigation as per standardised treatment pathway 18.

          8. Able to handle smartphone/tablet.

        Exclusion Criteria:

          1. Any confirmed or suspected diagnosis of anal or rectal stenosis, active inflammatory
             bowel disease, acute diverticulitis, severe diverticulosis, colorectal cancer,
             ischemic colitis, history of life-threatening autonomic dysreflexia, bleeding
             disorders, unspecified peri-anal conditions.

          2. Untreated rectal impaction.

          3. Any radiotherapy to the pelvis.

          4. Any current treatment with anticoagulants (not including aspirin or clopidogrel).

          5. Any current treatment with long-term systemic steroid medication (not including
             inhalation agents and/or local topical treatment).

          6. Current use of prokinetics.

          7. Any prior rectal or colonic surgery (not including anal procedures &gt;3 months ago, e.g.
             haemorrhoid excision).

          8. Anal, rectal and/or colonic endoscopic polypectomy within the previous 4 weeks.

          9. Overt or planned pregnancy.

         10. Ongoing symptomatic UTI as judged by investigator.

         11. Diagnosed psychiatric illness, considered as unstable by the investigator.

         12. Diagnosed with MS.

         13. Involvement in the planning and conduct of the study (applies to both WHC staff and
             staff at the study site).

         14. Previous enrolment in the present study.

         15. Simultaneous participation in another clinical study that may interfere with the
             present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susanne Lindholm</last_name>
    <phone>+46 31 376 45 03</phone>
    <email>Susanne.lindholm@wellspect.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anton Emmanuel, Dr.</last_name>
    <email>a.emmanuel@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Christensen, Prof.</last_name>
      <email>petchris@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital St Jacques</name>
      <address>
        <city>Nantes</city>
        <state>Rennes</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Perrouin-Verbe, Prof.</last_name>
      <email>brigitte.perrouinverbe@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka Gmbh</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Kurze, Dr.</last_name>
      <email>ines.kurze@zentralklinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BG-Klinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Bothig, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montecatone Rehabilitation Institute, Università di Bologna</name>
      <address>
        <city>Imola</city>
        <state>Bologna</state>
        <zip>40026</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Bazzocchi, Prof.</last_name>
      <email>gabriele.bazzocchi@unibo.it</email>
    </contact>
    <contact_backup>
      <last_name>Gabriele Bazzocchi, Prof.</last_name>
      <email>bazzocchi@montecatone.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera- Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Florence</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Del Popolo, Dr.</last_name>
      <email>delpopolog@aou-careggi.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnaas Sykehus HF</name>
      <address>
        <city>Nesoddtangen</city>
        <zip>1450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Glott, Dr.</last_name>
      <email>thomas.glott@sunnaas.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Lesionados Medulares Hospital Traumatología</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalez Viejo, Dr.</last_name>
      <email>maglezviejo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria E Ferreiro, Dr.</last_name>
      <email>MA.Elena.Ferreiro.Velasco@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologiska kliniken, Avd R18 Karolinska Universitetssjukhuset, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claes Hultling, Prof.</last_name>
      <email>claes@spinalis.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Physiology Unit, University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Emmanuel, Prof.</last_name>
      <email>a.emmanuel@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurogenic Bowel</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

